RxDoctor Payments Data

Christopher Maynard, MD

Internal Medicine · Athens, TNNPI 1750386819

Payments from drug & device makers

$1,743in general payments, 2019–2025

Across 114 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$447
  • GSK$225
  • AbbVie$216
  • Novartis$146
  • Pfizer$136
  • E.r. Squibb & Sons, L.L.C.$81
  • plus $492 from 14 others

What the payments were for

  • Food & beverage$1,743100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,743 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$331,333
Medicare patients
543
Services billed
10,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$141,320
JardianceEmpagliflozin81$79,651
OzempicSemaglutide45$75,067
TrulicityDulaglutide77$74,676
XareltoRivaroxaban74$70,989
MounjaroTirzepatide40$42,265
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$40,928
AbrysvoRsv Vacc, Pref A And Pref B/Pf128$40,857
FarxigaDapagliflozin Propanediol37$31,033
GlyxambiEmpagliflozin/Linagliptin34$28,096
Repatha SureclickEvolocumab28$27,738
Breo ElliptaFluticasone/Vilanterol48$22,148
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$20,981
LinzessLinaclotide19$18,106
ShingrixVaricella-Zoster Ge/As01b/Pf79$17,625

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$136$182,177256 claims
Lilly USA, LLCTrulicity, Mounjaro$47$116,941117 claims
Boehringer IngelheimJardiance, Glyxambi$16$107,747115 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta$225$88,669194 claims
Novo NordiskOzempic$67$75,06745 claims
Johnson & JohnsonXarelto$32$70,98974 claims
AstraZenecaFarxiga$44$31,03337 claims
AbbVieLinzess, Synthroid$216$20,91074 claims
NovartisEntresto$146$14,05316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Athens

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →